Overview

Bexarotene in Treating Patients With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of bexarotene in treating patients who have metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Ligand Pharmaceuticals
Treatments:
Bexarotene